How To Order

Getting Started With ADSTILADRIN


Ferring Pharmaceuticals is committed to ensuring a seamless ADSTILADRIN ordering experience

Step 1

Patient identification and submission of Patient Enrollment Form

  • Submit a completed Patient Enrollment Form: Once a patient has been identified, submit the form by fax to 1-833-322-5233 or online via You will receive a notification via email that your form has been successfully submitted
  • Ferring Access Support will conduct a benefits investigation.* Upon completion, Ferring Access Support will contact you via phone and/or fax with a benefits investigation summary, which will include details regarding the patient’s coverage:
    • Support options may be available for the patient
    • Results may include notifying your office of prior authorization requirements

ADSTILADRIN has confirmed 99% coverage for commercial and government-
insured patients1

Download these helpful resources:

ADSTILADRIN Copay Program Leave Behind Downloadable Guide
Copay Program Leave Behind

Create an account, register and enroll patients,
and submit claims on

Eligible, commercially insured patients may pay as little as $100for each ADSTILADRIN prescription

Step 2

Account setup and ordering ADSTILADRIN

  • Please validate that your practice location has an active account set up with either Besse Medical or Optum Frontier Therapies
  • Account setup: If there is not an active account, please set up an account with Besse Medical by phone at 1-800-252-87591-800-252-8759 or by email at or with Optum Frontier Therapies by email at
    • Note: Account setup may take 3 to 5 business days provided that all information and documentation submitted are complete
  • Ordering ADSTILADRIN: Once benefits coverage is confirmed, you can proceed to order
    • To order through the specialty distributor, contact Besse Medical at 1-800-252-87591-800-252-8759 or Optum Frontier Therapies at 1-833-754-64571-833-754-6457
    • If ordering through the specialty pharmacy, Ferring Access Support will triage your prescription to Optum Frontier Therapies (1-855-768-97271-855-768-9727), and the patient and practice will be contacted by both Optum Frontier Therapies and Ferring Access Support

Flexible payment terms:
Ferring offers 120-day payment terms

Step 3

Instillation of ADSTILADRIN

  • Schedule the instillation appointment with your patient—intravesical administration

For assistance, call 1-844-NADOnow1-844-NADOnow (1-844-623-66691-844-623-6669)
Monday to Friday, 9 AM to 6 PM ET

Watch video

ADSTILADRIN Ordering Walk-Through

Neal Shore, MD, FACS, a clinician from the ADSTILADRIN clinical trials, provides helpful details about how to order ADSTILADRIN.

Play video
Play video popup

Ferring Access Support is here for your patients and clinic

Ferring Access Support is a strong, integrated hub service to enhance the patient experience and drive reimbursement confidence and process within urology.

investigation support

Benefits investigation support

Benefits investigation support

  • Determine patient coverage for ADSTILADRIN, procedure, and site of care
  • Verify whether prior authorization/precertification is required and what is needed for submission
  • Provide support and guidance on applicable billing, coding, claims, and appeals
Hand and money icon

Patient support services

Patient support services

  • ADSTILADRIN Copay Program
    • Eligible, commercially insured patients may pay as little as $100 for ADSTILADRIN
  • Ferring Access Support Patient Assistance Program (PAP) for uninsured/underinsured patients who meet eligibility criteria§
  • Referrals to third-party organizations including 501c3 charitable organizations, patient support and education groups, and state health exchange resources
  • Appointment scheduling assistance and adherence support

Fulfillment services

Fulfillment services

  • Support and streamlining of the ADSTILADRIN ordering and delivery process
  • Coordination of product shipment and patient instillation
  • ADSTILADRIN product replacement

Dedicated reimbursement support

Dedicated reimbursement support

  • Dedicated team of specialists for all your coverage, access, and reimbursement needs
  • Case Managers and Field Reimbursement Managers
*Only commercially insured patients will go through a benefits verification.
Available only for patients who meet eligibility requirements. Program does not cover the cost of administration, office visits, or any associated costs. Terms and conditions apply. Offer expires 12/31/24.
Ferring offers approximately 120-day payment terms to its specialty distribution network. Payment terms offered from specialty distributor to HCP may vary.
§The ADSTILADRIN Patient Assistance Program (PAP) is only available for qualified patients enrolled in Ferring Access Support Program. Participation in the PAP is free. Ferring does not collect any fees from people seeking assistance through PAP. Assistance is provided in the form of free product shipped to site of administration. ADSTILADRIN must be secured at the site of administration until the qualified PAP patient’s treatment date, and the medicine must be provided only to the eligible patient at no charge of any kind for the product. ADSTILADRIN PAP only covers the cost of the product and not administration or other services. Any medications supplied by Ferring as a result of enrollment in the PAP are for the use of the named patient only and will not be sold, traded, bartered, transferred, returned for credit, or submitted to any third party (such as Medicare, Medicaid, or other benefit provider) for reimbursement. If ADSTILADRIN is no longer medically necessary for a qualified patient’s treatment or if the patient’s insurance or financial status changes, this must be reported to Ferring Access Support Program. If patient authorization is signed, electronic verification of a patient’s financial status is available to help determine eligibility. PAP beneficiaries with government insurance are eligible to obtain medication through the end of the calendar year. PAP beneficiaries with commercial insurance are eligible to obtain medication for up to 12 months. Healthcare Providers may not submit claims or payment from this medication through an insurance plan of any kind. Patients may not seek true out-of-pocket (TrOOP) or other insurance credit for medication provided through the PAP. If applicable, PAP recipients will have their health plans receive written notification. Ferring may change or cancel the PAP at any time and Ferring reserves the right to terminate a patient’s enrollment in the PAP at any time.
Terms and conditions may apply.

Sign Up to Receive Information and Updates on ADSTILADRIN (nadofaragene firadenovec-vncg)

Form Toggle

Your Information

Your Mailing Address

*Required field.

Reference: 1. Ferring Access Support benefits investigations for commercial and government-insured patients through March 15, 2024.

Important Safety Information


ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.


CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.


  • Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
  • Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.

DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.

USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.

ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).

You are encouraged to report negative side effects of prescription drugs to FDA. Visit or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.

Please see full Prescribing Information for ADSTILADRIN.

Close popup

Are you a US healthcare professional?

Latest Updates


Effective April 1, 2024, ADSTILADRIN has established an average sales price (ASP) in accordance with the guidelines set forth by the Centers for Medicare & Medicaid Services Part B. This determination is a significant milestone for Ferring Uro-Oncology and represents our commitment to providing transparency and value to our customers.

To get ongoing updates about ADSTILADRIN, please sign up here.